Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on July 23, 2021. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: James P. Kelly, Executive Vice-President and Chief Financial Officer, resigned effective August 13, 2021, to join another company.
- Appointment of New CFO: Timothy C. Dec was appointed Senior Vice-President and Chief Financial Officer, effective August 23, 2021.
- Compensation Structure: Mr. Dec's compensation package includes an annual base salary of $375,000, a target bonus of up to 40% of his annual salary, and an award of 85,000 stock options vesting over four years.
- Retention Agreement: An Executive Retention Agreement provides for 12 months of base salary and health benefits upon termination without cause or for good reason. In the event of a change in control, the agreement includes a lump-sum bonus payment and full vesting of stock-based compensation.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the transition of financial leadership and the potential financial obligations under the new Executive Retention Agreement in the event of a change in control or specific terminations.
Investor Verification Checklist
- Verify the effective dates of the CFO transition (August 13, 2021, for departure; August 23, 2021, for appointment).
- Review the full text of the Executive Retention Agreement (referenced as filed in a prior 8-K) to understand specific definitions of "cause" and "good reason."
- Confirm the vesting schedule and terms of the 85,000 stock options granted to the new CFO under the 2021 Equity Incentive Plan.
- Monitor subsequent filings for any impact on the company's financial reporting or strategic direction following the leadership change.